About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.


Seasonal allergies, diabetes and post-partum depression affect breastfeeding women worldwide. But there is very little information available about the transfer of drugs to breast milk and infants. Women who are breastfeeding are rarely included in clinical trials, but they still deserve to know if their medicines are safe. ConcePTION researchers recently published a paper in the Journal of Chromatography B that describes two developed and validated methods to determine how much of a drug the mother takes also transfers to her breastmilk, and potentially to her infant.  | READ MORE >>
Pregnancy is usually not recommended for women suffering from pulmonary arterial hypertension (PAH), a condition characterised by high blood pressure in the lung arteries, because of the high maternal mortality rate. For this reason, there is little to no information about whether or not the medicines these women use are safe during pregnancy and breastfeeding. A recent ConcePTION case report follows and presents the clinical and pharmacokinetic (PK) data of one breastfeeding mother living with PAH and her infant, who were both exposed to medicines used to treat the condition, bosentan and sildenafil, when the infant was 21 months old.  | READ MORE >>
The League of League of European Research Universities LERU have published recommendations for good practice in communicating animal research at universities: Putting emphasis on an open and transparent approach. In response to this call, the IMI ConcePTION project have worked to build the consortium ‘s capacity to communicate about animal data: Building a foundation of knowledge about animal data and animal welfare in the consortium.  | READ MORE >>


Increasing the volume and quality of information available about medicine use in #pregnancy and #breastfeeding is important. Parents and health care professionals can all contribute! @amalia_alexe explains the ConcePTION app and how it will support 👇


#ESDPPP2022 @EvaDegraeuwe presenting on experience of forming paediatric clinical trial networks in Belgium. It is very helpful to share experiences and learning across Europe @NIHRCRF_Lpool @CRFalderhey @IMIConcePTION @Pharmaforkids

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.


The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.